Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients. the DecubICUs study

01 Pubblicazione su rivista
Labeau Sonia O., Afonso Elsa, Benbenishty Julie, Blackwood Bronagh, Boulanger Carole, François Guy, Honore Patrick M., Rose Louise, Jankovi Radmilo, Brett Ashish K. Khanna Stephen J., Calvino‐Gunther Silvia, Chaboyer Wendy, Coyer Fiona, Deschepper Mieke, Llaurado‐Serra Mireia, Rubulotta Francesca, Saager Leif, Williams Ged, l Blot and DecubICUS study team Stijn, Rocco Monica, Alampi Daniela
ISSN: 1432-1238

Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and fac‐ tors associated with ICU‐acquired pressure injuries in adult ICU patients.
Methods: International 1‐day point‐prevalence study; follow‐up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU‐acquired pressure injury and hospital mortality were assessed by generalised linear mixed‐effects regression analysis.
Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU‐acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU‐acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU‐acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score < 19, ICU stay > 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower‐middle income‐economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3).

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma